Last reviewed · How we verify
TDM1
At a glance
| Generic name | TDM1 |
|---|---|
| Also known as | no other names |
| Sponsor | David Garcia Cinca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers (PHASE2)
- Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment. (PHASE2)
- Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) (PHASE2)
- Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer (PHASE2)
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (PHASE1, PHASE2)
- Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer
- HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TDM1 CI brief — competitive landscape report
- TDM1 updates RSS · CI watch RSS
- David Garcia Cinca portfolio CI